Canaccord reiterates Acadia Pharmaceuticals stock rating on Q1 results

Canaccord reiterated a Buy rating and $32 price target on Acadia Pharmaceuticals after Q1 2026 results, even as the company posted an EPS miss of $0.02 vs. $0.05 expected and revenue of $268 million vs. $280.92 million consensus. Nuplazid sales of $166.9 million and Daybue sales of $101.2 million both came in below estimates, but Acadia said refill timing issues were resolved and maintained its 2026 sales outlook. The stock remains supported by the remlifanserin Phase 2 readout expected between August and October 2026 and broader Daybue Stix availability.

Analysis

The market is treating this as a low-quality “miss that doesn’t matter” because the real debate is no longer the quarter, but whether the franchise can keep compounding through the second half. With a highly recurring product base, the main second-order effect is that near-term disappointment may actually pull forward attention to the pipeline as the cleaner source of upside, especially if investors conclude the approved assets are already in the price. That creates a setup where any stabilization in prescription velocity can re-rate the equity faster than the operating numbers alone would imply.

The more interesting dynamic is competitive: if the refill lag was truly a timing issue, then the near-term channel risk is to sentiment rather than demand, and competitors are unlikely to gain lasting share. But if reimbursement friction or adherence softness is broader than management suggests, then the weakness can quietly persist into the next two quarters and cap multiple expansion. The key tell is whether sequential growth re-accelerates without incremental promotional spend; if not, margin protection becomes the hidden pressure point.

The contrarian view is that the tape may be underpricing how much embedded optionality sits in the Alzheimer’s psychosis readout versus how little credit the market is giving the existing cash-flow engine. For a sub-$4B name with a low multiple, the equity can absorb modest execution noise if investors believe the pipeline event is binary and asymmetric. The risk is that a clean quarter is still needed to prevent the stock from becoming a tradeable squeeze rather than a durable re-rating story.

Key Decisions for Investors

• Stay tactically long ACAD into the next 2-6 weeks only if you can tolerate event volatility; the setup favors momentum continuation, but stop out if the stock loses the post-earnings gap and volume fails to hold.
• Buy ACAD Jan/Apr 2027 upside calls or call spreads to express the pipeline optionality with limited downside; the payoff is best if the market starts pricing the Alzheimer’s psychosis readout as a real catalyst over the next 3-5 months.
• For event-driven accounts, pair long ACAD vs. short a basket of higher-multiple CNS/biotech names with weaker balance sheets; this isolates the ‘approved products + pipeline optionality’ valuation gap while reducing market beta.
• Avoid chasing common stock after a multi-day gap unless you have a catalyst calendar; the near-term upside from the quarter is likely smaller than the downside if the next data point shows any follow-through weakness in prescription momentum.
• If you already own ACAD from lower levels, consider monetizing 25-50% into strength and retaining the rest via options; that keeps exposure to a positive re-rating while reducing the risk of a sentiment reset on the next guidance check.